Zhejiang Anglikang Pharmaceutical (002940.SZ): Pregabalin capsules (75mg, 150mg) have obtained drug registration certificate.

Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that the company has recently received the "Drug Registration Certificate" for Pregabalin Capsules (75mg, 150mg) issued by the National Medical Products Administration. Pregabalin capsules are used to treat post-herpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial onset seizures in adults. The company received a notification of acceptance for the application for the marketing authorization of Pregabalin Capsules (75mg, 150mg) in August 2023, and has now received approval from the National Medical Products Administration. According to national regulations, the receipt of the "Drug Registration Certificate" is considered equivalent to passing a consistency evaluation.